<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069922</url>
  </required_header>
  <id_info>
    <org_study_id>21-3710</org_study_id>
    <nct_id>NCT05069922</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Fresh Frozen Plasma Versus Albumin in Acute Burn Resuscitation</brief_title>
  <acronym>FFP vs Albumin</acronym>
  <official_title>Randomized Trial of Fresh Frozen Plasma Versus Albumin in Acute Burn Resuscitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a prospective randomized trial to study fresh frozen plasma (FFP)&#xD;
      versus albumin to determine the optimal colloid in burn resuscitations. This work addresses&#xD;
      both FY20 focus areas, prolonged field care (PFC) and en route care, along with mitigating&#xD;
      secondary effects of acute intervention, such as prevention of over resuscitation. Future&#xD;
      military conflicts anticipate more extensive burn and blast injuries, and delayed evacuation.&#xD;
      Therefore, the direct comparison of colloids used in burn resuscitation is critical to&#xD;
      advancing battlefield medicine. Specifically, this work will provide the foundation for the&#xD;
      use of freeze-dried plasma (FDP) in burn care by medical responders in PFC and en route care&#xD;
      scenarios. The investigators hypothesize that FFP administration, and later FDP, in burn&#xD;
      resuscitation is as safe as albumin, and more efficacious, in both reducing the total volume&#xD;
      of fluid required in acute burn resuscitation and correcting burn endotheliopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1: The investigators will evaluate the total fluids administered in FFP&#xD;
      (intervention) and albumin (control) groups. The investigators propose that the FFP group&#xD;
      will require less total fluids administered.&#xD;
&#xD;
      Specific Aim 2:The investigators will determine overall complication rates (pulmonary&#xD;
      complications, ARDS, ACS, over-resuscitation) in the FFP (intervention) and albumin (control)&#xD;
      administration groups. The investigators propose FFP administration will reduce the frequency&#xD;
      of these complications.&#xD;
&#xD;
      Specific Aim 3: The investigators will characterize the effects of FFP and albumin&#xD;
      administration on endothelial dysfunction in major burns. We will measure glycocalyx&#xD;
      degradation products (e.g. syndecan-1, glycosaminoglycans) in the serum. The investigators&#xD;
      project FFP will mitigate GDP better than albumin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total volume of fluid administered in 24 hours in each group (FFP or albumin), measured as mL/kg/%TBSA burned.</measure>
    <time_frame>3 years</time_frame>
    <description>Total volume</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Fresh Frozen Plasma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At 6-8 hours, Initiate FFP infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At 7 hours, Initiate 5% Albumin infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fresh Frozen Plasma</intervention_name>
    <description>Fresh Frozen Plasma</description>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_label>Fresh Frozen Plasma</arm_group_label>
    <other_name>Albumin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult thermal injury patients aged 2:18 years old with burns -&gt;20% TBSA seen at UCH&#xD;
             Burn Center within 8 hours of burn injury&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant patients, prisoners, Jehovah's Witness/inability to receive human blood&#xD;
             product/component therapy, electrical injury, chemical injury, friction/shear injury,&#xD;
             anticipated death within 48 hours of admission, delayed intervention (&gt;8 hours post&#xD;
             burn), history of renal failure requiring dialysis, Stage IV or V chronic kidney&#xD;
             disease, coagulopathy (admission INR &gt;2.5), cirrhosis (Childs B,C), concomitant life&#xD;
             threatening traumatic injuries, receiving blood product transfusion for another&#xD;
             reason, inability to obtain consent from patient or legally authorized representative.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Burn resuscitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be compiled and shared with Department of Defense</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

